London: A targeted three-drug combination therapy resulted in median overall survival of nine months for patients with advanced bowel cancer compared to 5.4 months for current standard-of-care treatment, showed the results of a phase-3 clinical trial. The data suggested that the three-drug combination, encorafenib, binimetinib and cetuximab, should replace chemotherapy for patients with metastatic colorectal […]
Copyright © 2024 - Odisha Television Limited All Rights Reserved.